<DOC>
	<DOCNO>NCT02191566</DOCNO>
	<brief_summary>After curative resection , patient stage IIIB-IV ( M0 ) gastric cancer give chemotherapy follow : S-1 orally 80 mg/m2 divide two daily dos 14 day oxaliplatin 130 mg/m2 intravenously 2 h every 21 day one cycle . S1 administer 16 cycle ( 12 month ) oxaliplatin 8 cycle ( 6 month ) .</brief_summary>
	<brief_title>S-1/Oxaliplatin High Risk Patients Who Underwent Gastrectomy</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients voluntarily provide write informed consent prior enter study Newly definitely diagnose primary gastric gastroesophageal junction adenocarcinoma histologically Patients underwent radical resection wide lymph node dissection TNM stage ( 6th AJCC ) IIIB IV postoperative staging Patients randomize within 6 week surgery Aged &lt; 20 year ≥ 76 year Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 Patients underwent surgery neoplasm stomach past History malignant disease The following case include study adequately treat basal cell squamous cell skin cancer , cervical carcinoma situ Gastric gastroesophageal junction adenocarcinoma distant metastasis ( M1 ) include distant lymph node ( behind pancreas , along aorta , portal vein , behind peritoneum , mesenteric lymph node ) Residual cancer postoperative staging ( R1 R2 resection ) Patients receive adjuvant chemotherapy , neoadjuvant chemotherapy and/or radiotherapy and/or immunotherapy past treatment gastric cancer Any follow within 6 month prior study recruitment : Myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass , NYHA class III IV congestive heart failure , stroke transient ischemic attack , serious cardiac arrhythmia require treatment Patients childbearing potential agree use generally accept effective method birth control study treatment period least 6 month end study treatment Pregnant woman , breastfeed woman , woman childbearing potential whose pregnancy test result positive• History hypersensitivity investigational product ( S1 Oxaliplatin )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Stomach Cancer</keyword>
</DOC>